Skip to content
DataLookout
Menu

NCT06596473

A Study of BG-C477 in Participants With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 6 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 36 versions: 28 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 31, 2027 to Jul 23, 2028 Show 4 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 3 words
    • Secondary endpoints: 13 to 16
    • Study description expanded, about 156 words
  2. Minor Study sites: 58 to 59v35
  3. Minor Trial sites expanded: 54 → 58 locationsv34
  4. Minor Site details revised at 1 of 54 sitesv33
  5. Minor Study sites: 52 to 54v32
  6. Minor Trial sites expanded: 49 → 52 locationsv31
  7. Minor Trial sites expanded: 41 → 49 locationsv30
  8. Minor Trial sites expanded: 32 → 41 locationsv29
  9. Minor Trial sites expanded: 25 → 32 locationsv28
  10. Minor Trial sites expanded: 21 → 25 locationsv27
  11. Minor Study sites: 19 to 21v26
  12. Minor Study sites: 17 to 19v25
  13. Minor Study sites: 16 to 17v24
  14. Notable Lead sponsor: BeiGene to BeOne Medicinesv23 Show 8 more changesShow less
    • Enrollment target: 21 to 310
    • Eligibility criteria expanded, about 75 words
    • Primary endpoints revised (5)
    • Study sites: 15 to 16
    • Primary and study completion dates: Oct 27, 2028 to Dec 31, 2027
    • Interventions: BG-C477 (Drug), Chemotherapy (Drug) to BG-C477 (Drug), Chemotherapy (Drug), Tislelizumab (Drug)
    • Secondary endpoints: details revised at 8 of 13 entries
    • Study description expanded, about 36 words
  15. Minor Study sites: 14 to 15v22
  16. Minor Study sites: 12 to 14v21
  17. Minor Study sites: 21 to 12v20
  18. Minor Study sites: 16 to 21v19
  19. Minor Study sites: 13 to 16v17
  20. Minor Site details revised at 4 of 13 sitesv10
  21. Minor Site details revised at 1 of 13 sitesv9
  22. Minor Site details revised at 3 of 13 sitesv8
  23. Minor Site details revised at 1 of 13 sitesv7
  24. Minor Site details revised at 1 of 13 sitesv5
  25. Minor Study sites: 3 to 13v4
  26. Minor Study sites: 1 to 3v3
  27. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 7, 2024 to Oct 3, 2024
    v2
  28. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: From first dose of the study drug(s) to 30 days after the last dose (up to approximately 2 years)
Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD)
Timeframe: Approximately 1 year
Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BG-C477
Timeframe: Approximately 1 year
Phase 1b: Overall Response Rate (ORR) assessed by the investigator
Timeframe: Approximately 2 years
Phase 1b: Recommended Phase 2 Dose (RP2D) of BG-C477
Timeframe: Approximately 2 years

Secondary (16)

Phase 1a: ORR assessed by the investigator
Phase 1a and 1b: Duration of Response (DOR) assessed by the investigator
Phase 1a and 1b: Disease Control Rate (DCR) assessed by the investigator
Phase 1b: Progression-Free Survival (PFS) assessed by the investigator
Phase 1b: Number of Participants with AEs and SAEs
Show 11 moreShow less
Phase 1a and 1b: Maximum observed plasma concentration (Cmax) of BG-C477 antibody-drug conjugate (ADC), BG-C477 total antibody, and free payload
Phase 1a and 1b: Minimum concentration (Cmin) of BG-C477
Phase 1a and 1b: Time to reach maximum observed plasma concentration (Tmax) of BG-C477
Phase 1a and 1b: Area under the concentration-versus-time curve during dosing interval (AUCtau) of BG-C477
Phase 1a and 1b: Apparent terminal elimination half-life (t1/2) of BG-C477
Phase 1a and 1b: Systemic clearance (CL/F) of BG-C477
Phase 1a and 1b: Apparent volume of distribution at steady state (Vss) of BG-C477
Phase 1b: Part A: ORR assessed by the Blinded Independent Central Review Committee (BICR)
Phase 1b: Part A: PFS assessed by the BICR
Phase 1b: Part A: DOR assessed by the BICR
Phase 1b: Part A: DCR assessed by the BICR

Arms and interventions

Phase 1a: BG-C477 Monotherapy Dose EscalationExperimental

Sequential cohorts of increasing dose levels of BG-C477 will be evaluated as monotherapy.

Phase 1a: BG-C477 Monotherapy Safety ExpansionExperimental

Selected dose levels of BG-C477 determined to be safe in Phase 1a dose escalation will be further evaluated in monotherapy.

Phase 1b Part A: BG-C477 Monotherapy Expansion and Dose OptimizationExperimental

Participants with selected advanced solid tumors will receive BG-C477 at the recommended doses for expansion (RDFEs) identified in Phase 1a.

Phase 1b Part B: Combination Therapy ExpansionExperimental

Participants with selected advanced solid tumors will receive BG-C477 at RDFEs identified in Phase 1a in combination with anticancer agents, including chemotherapy or tislelizumab.

Drugs: BG-C477, Tislelizumab, Chemotherapy

Sites

59 sites in 8 countries

China 26, United States 10, Australia 6, Malaysia 5, Japan 4, South Korea 4, Thailand 3, New Zealand 1